

Investor News

No. 4/2014

## Zealand to present at 39<sup>th</sup> Annual Deutsche Bank Healthcare Conference in Boston

*Copenhagen, 1 May 2014* – Zealand Pharma A/S (Zealand) (CVR no. 20 04 50 78) (NASDAQ OMX Copenhagen: ZEAL) informs that the Company will present at the 39<sup>th</sup> Annual Deutsche Bank Healthcare Conference on May 7 – 8, 2014 at the InterContinental Hotel in Boston, US.

Date and time of presentation: **Wednesday 7 May 2014 at 4.50 pm ET**

Presenter: **David Solomon, President and Chief Executive Officer**

In the presentation, David Solomon will give an update on the status and outlook for the main assets in Zealand's portfolio of peptide therapeutic medicine candidates.

Please note that no new financial or other material new information relating to Zealand will be disclosed at the above listed conference.

**\*\*\***

### **For further information, please contact:**

Hanne Leth Hillman, Vice President,  
Head of Investor Relations & Corporate Communications  
Tel: +45 50 60 36 89, email: [hlh@zealandpharma.com](mailto:hlh@zealandpharma.com)



### **About Zealand**

Zealand Pharma A/S (Zealand) (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and a mature portfolio of therapeutic products, which are all based on internal inventions. The company's focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead product is lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, marketed as Lyxumia® under a license agreement with Sanofi. Lyxumia® is approved in several countries globally, including Europe and Japan. In the US, submission of an NDA is expected in 2015, after completion of a cardiovascular outcome study, ELIXA. A once-daily single injection combination of Lyxumia® and Lantus® (LixiLan) is in Phase III development with planned first regulatory filing in end 2015.

Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.

For further information: [www.zealandpharma.com](http://www.zealandpharma.com)

Follow us on Twitter @ZealandPharma